Analysts' ratings for Neurocrine Biosciences (NASDAQ:NBIX) over the last quarter vary from bullish to bearish, as provided by 16 analysts.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 5 | 9 | 2 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 1 | 0 | 0 | 0 |
| 2M Ago | 1 | 2 | 0 | 0 | 0 |
| 3M Ago | 4 | 5 | 2 | 0 | 0 |
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $167.94, a high estimate of $216.00, and a low estimate of $138.00. This upward trend is apparent, with the current average reflecting a 5.89% increase from the previous average price target of $158.60.
Understanding Analyst Ratings: A Comprehensive Breakdown
A clear picture of Neurocrine...
Login or create a forever free account to read this news
Sign up/Log in